Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
arterial and venous thrombotic manifestations and/or pregnancy-related complications in …

Abstract Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the
body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that …

Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …

Background The McMaster RARE‐Bestpractices project group selected the catastrophic
antiphospholipid syndrome (CAPS) for a pilot exercise in guideline development for a rare …

Aim To evaluate the magnitude of venous and arterial thrombosis risk associated with
antiphospholipid antibodies (APLs) in adults without systemic lupus erythematosus (SLE) …

According to classification criteria for antiphospholipid syndrome (APS), laboratory
diagnosis is based on the detection of antiphospholipid antibodies (aPL) by immunological …

Antiphospholipid antibodies (aPL) comprise a panel of autoantibodies that reflect a potential
prothrombotic risk in several autoimmune conditions, most notably antiphospholipid …

Background Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS)
classification criteria to include IgG/IgM anti-β2-glycoprotein (aβ2GPI) antibodies in addition …

The classification criteria for antiphospholipid syndrome (APS) generate discussion, with a
growing impression that certain patients not fulfilling these criteria might be inadequately …